Rao, Patricia,Ponath, Paul,Ponte, Jose F.,Smith, L. Mary,Rosenzweig, Michael
申请号：
AU2006261127
公开号：
AU2006261127B2
申请日:
2006.06.19
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). The binding molecules of the invention are characterized by binding to hILT3 with high affinity and downmodulating immune responses in vitro, e.g., downmodulating alloimmune responses； the production of inflammatory cytokines by dendritic cells, e.g., monocyte-derived dendritic cells (MDDC)； the upregulation of costimulatory molecules by DC, e.g., MDDC； and/or calcium flux in monocytes. In addition, the binding molecules upregulate the expression of inhibitory receptors on dendritic cells, e.g., immature dendritic cells. Surprisingly, these same binding molecules which downmodulate immune responses in vitro, are immunostimulatory in vivo. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof. Methods of using the binding molecules of the invention to detect human ILT3 or to modulate human ILT3 activity, either in vitro or in vivo, are also encompassed by the invention.
